WASHINGTON, Aug. 30, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of U.S. Patent No. 9,138,432 ("the '432 patent"). The '432 patent was issued by the USPTO in September 2015 and expires in September 2025.
Vanda had previously announced on August 25, 2016 that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane infringed U.S. Patent Nos. RE39,198 ("the '198 Patent") and 8,586,610 ("the '610 Patent") and accordingly issued an injunction barring Roxane from marketing its product until the expiration of the later expiring '610 patent on November 2, 2027.
About Vanda Pharmaceuticals Inc.
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals, please visit www.vandapharma.com.
Fanapt® is a registered trademark of Vanda Pharmaceuticals Inc.
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
Group Vice President
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uspto-dismisses-petition-for-inter-partes-review-of-fanapt-patent-300320203.html
SOURCE Vanda Pharmaceuticals Inc.